MergerMay 15, 2026, 08:22 AM
Pulmatrix Announces Merger with Eos SENOLYTIX; Q1 Net Loss $1.17M
AI Summary
Pulmatrix, Inc. announced its first quarter 2026 financial results and provided a corporate update, highlighting its merger agreement with Eos SENOLYTIX. The proposed merger, anticipated to close in Q3 2026, is a strategic move for the company. Pulmatrix also secured $1.0 million from a private placement of preferred stock and reported a reduced net loss of $1.17 million for Q1 2026, down from $1.81 million in Q1 2025. The company continues to focus on monetizing its iSPERSE™ technology and clinical assets.
Key Highlights
- Announced merger agreement with Eos SENOLYTIX on March 26, 2026.
- Secured $1.0 million gross proceeds from a private placement of preferred stock.
- Common stockholders to receive approximately 6% interest in the new combined company.
- Q1 2026 net loss was $1.17 million, an improvement from $1.81 million in Q1 2025.
- Q1 2026 research and development expenses were less than $0.1 million.
- Q1 2026 general and administrative expenses decreased to $1.3 million from $1.8 million in Q1 2025.
- Cash and cash equivalents totaled $3.3 million as of March 31, 2026.
- Company is actively seeking to out-license or monetize its clinical assets.
Price Impact
More from PULM